

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **POLL RESULTS OF EXTRAORDINARY GENERAL MEETING**

The Board is pleased to announce that all the resolutions as set out in the EGM Notice dated 12 August 2016 were duly passed at the EGM held on 14 October 2016.

### **RESULTS OF THE EGM**

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**Circular**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), both dated 12 August 2016, and the announcement of postponement of extraordinary general meeting and change of book closure period of the Company dated 23 August 2016. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context herein requires otherwise.

The board of directors (the “**Board**”) is pleased to announce that all the resolutions as set out in the EGM Notice were duly passed by way of poll at the extraordinary general meeting (the “**EGM**”) held on 14 October 2016.

As at the date of the EGM, the Company had 1,595,000,000 Shares in issue including 697,500,000 Domestic Shares and 897,500,000 H Shares. Prior to the date of the EGM, Shareholders holding 1,563,999,500 Shares, representing approximately 98.06% of the total number of Shares in issue as at the date of the EGM, lodged to the Company that they will attend the EGM either in person or by proxy. The actual number of the Shares attending the EGM either in person or by proxy was 891,825,000, representing approximately 55.91% of the total number of the Shares in issue as at the date of the EGM. The holding of the EGM complies with the Company Law of the PRC and the Articles.

No Shareholder was required to abstain from voting in respect of the resolutions at the EGM. As such, there were a total of 1,595,000,000 Shares entitling the Shareholders to attend and vote on the resolutions at the EGM.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 17.47A of the GEM Listing Rules. No Shareholder has stated in his/her/its intention to vote against or to abstain from voting on any of the resolutions at the EGM.

Details of the poll results in respect of the ordinary resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(1)	To appoint Mr. Liu Renmu as a non-executive director of the Company	891,825,000 shares 100%	0 shares 0%	891,825,000 shares
(2)	To authorize the board of directors to fix the remuneration of the appointed director	891,825,000 shares 100%	0 shares 0%	891,825,000 shares

*Note:* The percentages of votes are based on the total number of Shares held by the Shareholders who voted at the EGM in person or by corporate representative or proxy.

As more than one-second of the votes present at the EGM either in person or by proxy was cast in favour of the above resolutions numbered (1) and (2), all the above resolutions were duly passed as ordinary resolutions.

Tianjin Zhong Yue CPA Firm (天津中悦會計師事務所), the Company's external accountants who are qualified to serve as its auditors was appointed as scrutineer of the EGM for the vote-taking.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
14 October 2016

*As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Wang Shuxin; the non-executive Directors of the Company are Feng Enqing, Chen Yingzhong and Liu Renmu; the independent non-executive Directors of the Company are Guan Tong, Wu Chen and Peter K.S. Chan.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website at <http://www.hkgem.com> on the Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*